The duo lay out how DESTINY-Breast 06 leapfrogged 04, bringing T-DXd into chemo-naïve HR-positive disease, doubling objective response, and, for the first time, enrolling tumors once written off as “HER2-zero”.
DB-04 to DB-06, the Steps of Ultra-Low
Recommended Videos
